Literature DB >> 1546186

Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation.

S J Knox1, M L Goris, B W Wessels.   

Abstract

As the field of radioimmunotherapy (RIT) continues to develop and looks increasingly promising, there is growing interest in the radiobiology of RIT. Recently, several investigators have conducted studies in animal models comparing the relative efficacy of RIT with dose equivalent external beam irradiation. Although these studies are the first of many to follow, the results are provocative and several patterns are suggested by the available data. The results of the studies are summarized and compared, and preliminary hypotheses that might explain the reported observations are discussed. In summary, results from studies comparing the efficacy of RIT with external beam irradiation have been variable and may be indicative of different underlying mechanisms. While the particular experimental model, design and methodology used to compare the efficacy of RIT with external beam irradiation are probably important influences upon subsequent observations, it appears that for a given tumor type, the size of the survival curve shoulder or alpha/beta ratio, and tumor doubling time are important determinants of the magnitude of the dose rate effect. When this effect is minimal, it is possible that other factors such as reoxygenation, the arrest of cells in G2, and selective targeting of tumor by radiolabelled antibody may explain, in part, the increased efficacy of RIT compared with external beam irradiation that has been observed in some systems.

Entities:  

Mesh:

Year:  1992        PMID: 1546186     DOI: 10.1016/0167-8140(92)90342-r

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  11 in total

Review 1.  Clinical radioimmunotherapy--the role of radiobiology.

Authors:  Jean-Pierre Pouget; Isabelle Navarro-Teulon; Manuel Bardiès; Nicolas Chouin; Guillaume Cartron; André Pèlegrin; David Azria
Journal:  Nat Rev Clin Oncol       Date:  2011-11-08       Impact factor: 66.675

2.  Investigation of the effects of treatment planning variables in small animal radiotherapy dose distributions.

Authors:  Amy R Motomura; Magdalena Bazalova; Hu Zhou; Paul J Keall; Edward E Graves
Journal:  Med Phys       Date:  2010-02       Impact factor: 4.071

3.  Development of a micro-computed tomography-based image-guided conformal radiotherapy system for small animals.

Authors:  Hu Zhou; Manuel Rodriguez; Fred van den Haak; Geoffrey Nelson; Rahil Jogani; Jiali Xu; Xinzhi Zhu; Yongjiang Xian; Phuoc T Tran; Dean W Felsher; Paul J Keall; Edward E Graves
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-04-13       Impact factor: 7.038

Review 4.  Radio-immunotherapy dosimetry with special emphasis on SPECT quantification and extracorporeal immuno-adsorption.

Authors:  S E Strand; M Ljungberg; J Tennvall; K Norrgren; M Garkavij
Journal:  Med Biol Eng Comput       Date:  1994-09       Impact factor: 2.602

Review 5.  Radiolabelled monoclonal antibodies in tumour imaging and therapy: out of fashion?

Authors:  A B Delaloye; B Delaloye
Journal:  Eur J Nucl Med       Date:  1995-06

6.  Dead cells in melanoma tumors provide abundant antigen for targeted delivery of ionizing radiation by a mAb to melanin.

Authors:  Ekaterina Dadachova; Joshua D Nosanchuk; Li Shi; Andrew D Schweitzer; Annie Frenkel; Jerome S Nosanchuk; Arturo Casadevall
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-05       Impact factor: 11.205

7.  Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer.

Authors:  J M de Klerk; B A Zonnenberg; A D van het Schip; A van Dijk; S H Han; J M Quirijnen; G H Blijham; P P van Rijk
Journal:  Eur J Nucl Med       Date:  1994-10

8.  131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma.

Authors:  Andrei Iagaru; Erik S Mittra; Kristen Ganjoo; Susan J Knox; Michael L Goris
Journal:  Mol Imaging Biol       Date:  2009-06-20       Impact factor: 3.488

9.  Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model.

Authors:  Nagarajan Vinod; Jae Hyung Kim; Seungbum Choi; Ilhan Lim
Journal:  Sci Rep       Date:  2021-06-18       Impact factor: 4.379

10.  Positron emission tomography agent 2-deoxy-2-[18F]fluoro-D-glucose has a therapeutic potential in breast cancer.

Authors:  Renee M Moadel; Andrew V Nguyen; Elaine Y Lin; Ping Lu; Joseph Mani; M Donald Blaufox; Jeffrey W Pollard; Ekaterina Dadachova
Journal:  Breast Cancer Res       Date:  2003-08-22       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.